The FDA has established a formal regulatory category for whole-room microbial-reduction devices, giving manufacturers a defined pathway for bringing these environmental-disinfection systems to market.

Under a final order effective Sept. 10, 2026, the agency classified the devices as Class II, meaning they require special controls and premarket notification through the 510(k) process. The category covers systems intended to reduce microbial contamination on medical-device surfaces throughout a room after standard cleaning and disinfection have been completed.

Manufacturers seeking clearance will need to demonstrate performance under real-world and worst-case conditions. FDA’s special controls address:

·       Microbial reduction effectiveness across the claimed treatment area.

·       Performance against each organism identified in product labeling.

·       Treatment times, device placement, and room-configuration limitations.

·       Risks associated with human exposure to the device’s energy or emissions.

·       Compatibility with medical devices and other materials in the room.

·       Electrical, mechanical, and software safety.

·       Safeguards preventing operation while a room is occupied.

·       Instructions for installation, operation, maintenance, and staff training.

The order follows FDA’s 2023 De Novo classification of Xenex Disinfection Services’ LightStrike+ system. That decision created the initial Class II category; the final order formally incorporates the device type and its special controls into federal regulations. Future manufacturers may now pursue 510(k) clearance by showing that their systems are substantially equivalent to an appropriate legally marketed predicate device.

The classification applies to supplemental whole-room treatment performed after manual cleaning and disinfection. It does not position these systems as replacements for routine environmental cleaning, nor does clearance alone establish that a device reduces healthcare-associated infections in clinical practice.

Why it matters: Until now, hospitals evaluating ultraviolet-light and other automated room-disinfection technologies often faced wide variations in vendor claims, testing methods, and regulatory status. The new classification gives infection prevention, environmental services, and purchasing teams a more consistent baseline for determining whether a product’s safety and microbial reduction claims have undergone FDA review.